No Data
Kazakh Triptych: Summary of the 2024 Annual Report
Kazakh Triptych: Report for the first quarter of 2025
Kazakh Triptych: 2024 Annual Report
Harbin Medisan Pharmaceutical (002900.SZ): A net loss of 28.845 million yuan in the first quarter.
Gelonghui reported on April 24 that Harbin Medisan Pharmaceutical (002900.SZ) announced its first quarterly report, with revenue of 0.205 billion yuan, a year-on-year decrease of 16.93%, a net loss of 28.845 million yuan, a non-recurring net loss of 29.329 million yuan, and a basic EPS of -0.09 yuan.
Harbin Medisan Pharmaceutical (002900.SZ): The USA's tariff policy on Pharmaceuticals will not affect the company's Business.
Gelonghui, April 10 - Harbin Medisan Pharmaceutical (002900.SZ) stated on the interactive platform that currently, the company's products are not exported to the USA, and the USA's tariff policy on Pharmaceuticals will not affect the company's Business.
Strong policies to maintain stability inject confidence, the Agriculture chain and CSI Consumer 360 index are expected to progress together.
Track the entire lifecycle of the main Sector.
